ASH 2024 Summary: Full or Reduced Dose Apixaban or Rivaroxaban for E…

2024 ASH Annual Meeting Insights Hub

J. Schaefer

Updates in Thrombosis and Anticoagulation

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

D. Garcia

CHEST 2024 Insights: Post COVID Cardiac Complications

CHEST Annual Meeting Insights

N. Ramesh

ASCO® GI 2025 Summary: Meta-Analysis of Phase II/III RCTs to Evaluat…

Insights from 2025 ASCO® GI Annual Meeting

K. Thein

ASH 2024 Review: Advances in VTE and Cancer-Associated Thrombosis

Cleveland Clinic Taussig Cancer Institute

K. Sanfilippo

How do I Recognize and Treat the VEXAS Syndrome?

Cleveland Clinic Department of Rheumatic and Immunologic Disease

P. Grayson

Cancer-Associated Thrombosis: Defining, Risk Assessment, and Prognos…

HemeHub

T. Bat, M. Carrier

Cancer-Associated Thrombosis: Anticoagulant Dose and Duration Consid…

HemeHub

T. Bat, M. Carrier

ASH 2024 Review: AI in Classical Hematology

Cleveland Clinic Taussig Cancer Institute

R. Patell

Management of Simultaneous Venous and Arterial Thromboembolic Disease

Scripps Health

J. May

Risk for Developing VTE in Pts With Compound Heterozygosity of FVL a…

Cleveland Clinic Taussig Cancer Institute

G. Gerber

Perioperative Considerations for Anticoagulation With Mechanical Dev…

James Douketis

Medical Jeopardy: 2024 Update

Scripps Health

J. Diamant

Hormonal Therapy and Thrombosis Risk in Women

Scripps Health

D. Houghton

Hormonal Therapy and Thrombosis Risk With Testosterone

Scripps Health

D. Houghton

EHA 2024 Insights: Low-Molecular-Weight Heparin and VTE in Newly Dia…

Insights from 2024 EHA Annual Meeting

M. Lauw

Cancer-Associated Thrombosis: Which Anticoagulant and Why

HemeHub

T. Bat, M. Carrier

Cancer-Associated Thrombosis: Choosing Factor XI and XIa Inhibitors

BMFcases

T. Bat, M. Carrier

Cancer-Associated Thrombosis: Assessing Bleeding Risk and When to Pr…

HemeHub

T. Bat, M. Carrier

2023 ISTH Insights: "The EVE Trial - Extending VTE Secondary Prevent…

Robert McBane